gandotinib   Click here for help

GtoPdb Ligand ID: 7909

Synonyms: LY-2784544 | LY2784544
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Gandotinib (LY2784544) is a potent ATP-competitive and selective JAK2 inhibitor [2], with potential clinical value for its ability to inhibit the constitutive activity of the JAK2V617F mutation found in myeloproliferative neoplasms (MPNs).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 83.37
Molecular weight 469.18
XLogP 4.58
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Clc1ccc(c(c1)F)Cc1c(C)nc2n1nc(Nc1n[nH]c(c1)C)cc2CN1CCOCC1
Isomeric SMILES Clc1ccc(c(c1)F)Cc1c(C)nc2n1nc(Nc1n[nH]c(c1)C)cc2CN1CCOCC1
InChI InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
InChI Key SQSZANZGUXWJEA-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
A Phase 2 clinical evalation of LY2784544 in patients with myeloproliferative neoplasms (NCT01594723) has been completed, with results published by Berdeja et al. (2018) [1]. In this study LY2784544 exhibited efficacy against JAK2 V617F-mutated myeloproliferative neoplasms.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
In vivo, gandotinib suppresses JAK2V617F-induced MPN pathogenesis in mouse tumour models. This appears to be the result of inhibition of JAK2V617F-mediated STAT5 phosphorylation.